Evidence map›Paper›PMID 36305561›Full record

Trial reportEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2023

Higher power short duration vs. lower power longer duration posterior wall ablation for atrial fibrillation and oesophageal injury outcomes: a prospective multi-centre randomized controlled study (Hi-Lo HEAT trial).

David Chieng, Louise Segan, Hariharan Sugumar, Ahmed Al-Kaisey, Joshua Hawson, Benjamin M Moore, Michael C Y Nam, Aleksandr Voskoboinik, Sandeep Prabhu, Liang-Han Ling and 7 more

Open access · bronzeAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Efficacy and safety of high-power short-duration ablation for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2024
    Pooled it
  4. Very high-power short-duration using 70W and a flexible tip ablation catheter for pulmonary vein isolation: the POWER PULSE randomized controlled trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Trial
  5. Trial
  6. Esophageal heating characteristics of very high-power short duration radiofrequency ablation in a myocardial phantom model.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026
    Article
  7. Article
  8. Minimizing Esophageal Heating During Radiofrequency Catheter Ablation.Journal of cardiovascular electrophysiology · 2026
    Article
  9. Article
  10. Review
  11. Article
  12. Esophageal endoscopic findings after pulmonary vein and posterior wall isolation using pulsed field ablation: results from the Eso-PFA study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Observational
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

David ChiengClinical Electrophysiology Research, Baker Heart and Diabetes Research Institute, 55 Commercial Road, Melbourne, Victoria 3004, Australia.ORCID 0000-0002-4164-0923
Louise SeganClinical Electrophysiology Research, Baker Heart and Diabetes Research Institute, 55 Commercial Road, Melbourne, Victoria 3004, Australia.ORCID 0000-0001-5585-6146
Hariharan SugumarClinical Electrophysiology Research, Baker Heart and Diabetes Research Institute, 55 Commercial Road, Melbourne, Victoria 3004, Australia.ORCID 0000-0003-2236-0413
Ahmed Al-KaiseySchool of Medicine, University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0001-5174-1034
Joshua HawsonSchool of Medicine, University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0002-8752-2412
Benjamin M MooreDepartment of Cardiology, Alfred Hospital, 55 Commercial Road, Melbourne, Victoria 3004, Australia.
Michael C Y NamDepartment of Cardiology, Alfred Hospital, 55 Commercial Road, Melbourne, Victoria 3004, Australia.ORCID 0000-0002-7946-1680
Aleksandr VoskoboinikClinical Electrophysiology Research, Baker Heart and Diabetes Research Institute, 55 Commercial Road, Melbourne, Victoria 3004, Australia.
Sandeep PrabhuClinical Electrophysiology Research, Baker Heart and Diabetes Research Institute, 55 Commercial Road, Melbourne, Victoria 3004, Australia.ORCID 0000-0002-2694-2245
Liang-Han LingClinical Electrophysiology Research, Baker Heart and Diabetes Research Institute, 55 Commercial Road, Melbourne, Victoria 3004, Australia.ORCID 0000-0001-8393-2337
Jer Fuu NgDepartment of Gastroenterology, Alfred Hospital, 55 Commercial Road, Melbourne, Victoria 3004, Australia.
Gregor BrownDepartment of Gastroenterology, Alfred Hospital, 55 Commercial Road, Melbourne, Victoria 3004, Australia.ORCID 0000-0002-9807-7537
Geoffrey LeeDepartment of Cardiology, Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia.
Joseph MortonDepartment of Cardiology, Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia.ORCID 0000-0003-1778-3729
Henry DebinskiDepartment of Cardiology, Cabrini Hospital, 181/183 Wattletree Road, Malvern, Victoria 3144, Australia.ORCID 0000-0001-9044-0402
Jonathan M KalmanSchool of Medicine, University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0002-6618-7184
Peter M KistlerClinical Electrophysiology Research, Baker Heart and Diabetes Research Institute, 55 Commercial Road, Melbourne, Victoria 3004, Australia.ORCID 0000-0001-5369-5844
Baker Heart and Diabetes Institute · AUThe Royal Melbourne Hospital · AUThe Alfred Hospital · AUCabrini Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsRadiofrequency (RF) ablation for pulmonary vein isolation (PVI) in atrial fibrillation (AF) is associated with the risk of oesophageal thermal injury (ETI). Higher power short duration (HPSD) ablation results in preferential local resistive heating over distal conductive heating. Although HPSD has become increasingly common, no randomized study has compared ETI risk with conventional lower power longer duration (LPLD) ablation. This study aims to compare HPSD vs. LPLD ablation on ETI risk. METHODS AND

resultsEighty-eight patients were randomized 1:1 to HPSD or LPLD posterior wall (PW) ablation. Posterior wall ablation was 40 W (HPSD group) or 25 W (LPLD group), with target AI (ablation index) 400/LSI (lesion size index) 4. Anterior wall ablation was 40-50 W, with a target AI 500-550/LSI 5-5.5. Endoscopy was performed on Day 1. The primary endpoint was ETI incidence. The mean age was 61 ± 9 years (31% females). The incidence of ETI (superficial ulcers n = 4) was 4.5%, with equal occurrence in HPSD and LPLD (P = 1.0). There was no difference in the median value of maximal oesophageal temperature (HPSD 38.6°C vs. LPLD 38.7°C, P = 0.43), or the median number of lesions per patient with temperature rise above 39°C (HPSD 1.5 vs. LPLD 2, P = 0.93). Radiofrequency ablation time (23.8 vs. 29.7 min, P < 0.01), PVI duration (46.5 vs. 59 min, P = 0.01), and procedure duration (133 vs. 150 min, P = 0.05) were reduced in HPSD. After a median follow-up of 12 months, AF recurrence was lower in HPSD (15.9% vs. LPLD 34.1%; hazard ratio 0.42, log-rank P = 0.04).

conclusionHigher power short duration ablation was associated with similarly low rates of ETI and shorter total/PVI RF ablation times when compared with LPLD ablation. Higher power short duration ablation is a safe and efficacious approach to PVI.

Indexed as

Atrial FibrillationCatheter AblationPulmonary VeinsRadiofrequency AblationAgedFemaleHot TemperatureHumansMaleMiddle AgedProspective StudiesRecurrenceTreatment OutcomeAtrial fibrillationHPSDLPLDOesophageal thermal injuryPulmonary vein isolationRadiofrequency

Identifiers

PMID36305561
PMCPMC9934996
OpenAlexW4307496701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.